ADVA
13.4.2021 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has successfully demonstrated interoperability between its next-generation FSP 3000 DCI open line system (OLS) and QSFP-DD 400ZR modules from Acacia Communications and Inphi Corporation. Conducted over a 120km amplified link, the tests show a clear path to commercial deployments of a complete solution with all the benefits of open, programmable networking. The trial featured 400Gbit/s WDM transport using low-power 400ZR pluggable QSFP-DD transceivers from Acacia and Inphi with ADVA’s FSP 3000 DCI OLS . It was carried out under real-world conditions with 400Gbit/s channels placed next to the test channels as well as a fully loaded spectrum. To validate three-way line-side interoperability, 400ZR was transmitted from Acacia to Inphi and vice versa. Test results showed that this multi-vendor ecosystem exceeds all OIF 400ZR Implementation Agreement performance metrics. Large-scale DCI network operators now have an easy and cost-effective route to a dynamic, future-proof and open environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005107/en/
“Today, we’re showing a direct route to open DCI networking using 400ZR. By proving the next-level interoperability of our platform with Acacia and Inphi’s optical interconnect technology, we’re empowering network operators to effortlessly harness the benefits of both 400ZR and open infrastructure. This will be key to reducing cost and complexity in the new breed of high-bandwidth DCI networks,” said Steve Penticost, VP, global business development, ADVA. “Others may talk about openness, but our track record with multi-vendor innovation speaks for itself. With thousands of our DCI OLS deployed, we’re already giving huge numbers of networks across the planet the freedom to select any components and leverage different innovation cycles.”
The ADVA FSP 3000 DCI OLS is the market’s most comprehensive OLS platform. Its open and modular design removes all restrictions of traditional closed systems and puts DCI network operators in complete control. With ADVA’s unrivalled experience of managing APIs in DCI architectures, the platform extends SDN to the transport layer. Designed to interoperate with all standards-based DWDM pluggable optics, the ADVA DCI OLS now features components specifically engineered to meet 400ZR DCI demands. The latest trials using a 120km single-mode fiber show that it exceeds 400ZR performance requirements under fully loaded conditions including 75GHz channel spacing, enabling an aggregate capacity of 26Tbit/s per fiber. ADVA’s DCI OLS and Acacia and Inphi’s QSFP-DD 400ZR modules offer operators a complete and validated solution built on best-of-breed components.
“Acacia has a long, proven history of pluggable silicon photonics innovation and has continually driven down the level of power consumption, size and cost of coherent interconnects,” said Tom Williams, VP, marketing, Acacia Communications. “400Gbit/s coherent pluggables enable network operators to support their growing bandwidth demands using power-efficient solutions that offer operational flexibility. By showcasing the interoperability of our high-performance coherent platform in a QSFP form factor with ADVA’s new DCI OLS, we’re giving DCI networks a clear path to a compact and cost-efficient optical layer assembled with best-in-class innovation.”
“With the introduction of COLORZ® 100G in 2016, Inphi’s silicon photonics-based QSFP transceivers along with ADVA’s line systems created a simpler and more cost-efficient way to connect data centers. Inphi’s COLORZ® II 400ZR QSFP-DD transceiver, with its low-power coherent DSP and silicon photonics engine, takes IP over DWDM to the next level. COLORZ® II 400ZR enables large cloud operators to connect metro data centers at a fraction of the cost of traditional coherent transport systems and allows switch and router companies to offer the same density for both coherent DWDM and client optics in the same chassis. Interoperable 400ZR solutions allow customers to deploy a validated ecosystem with our innovative low-power, high-performing pluggable solutions and ADVA’s next-generation DCI OLS,” said Josef Berger, AVP, optical interconnect, Inphi. “400ZR empowers DCI operators to select best-in-class components that reduce the total cost of ownership of their cloud networks.”
More information on the demo is available in these slides: https://adva.li/acacia-inphi-demo-slides .
Watch this video for further details on the new ADVA DCI OLS: https://youtu.be/8zI3E46oMBo .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
All trademarks used herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005107/en/
Social Media:
https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
